Skip to content

Study · Systematic review · 2024

2 results

Anti-obesity pharmacological agents for polycystic ovary syndrome: A systematic review and meta-analysis to inform the 2023 international evidence-based guideline.

Goldberg A, Graca S, Liu J, Rao V, Witchel SF, Pena A, Li R, Mousa A, Tay CT, Pattuwage L, Teede H, Yildiz BO, Ee C

Obesity reviews : an official journal of the International Association for the Study of Obesity14 Feb 2024Cited by 43 (Europe PMC)

PMID38355887 (opens in a new tab)DOI10.1111/obr.13704 (opens in a new tab)PepBankPUB-38355887
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

This systematic review and meta-analysis evaluated the efficacy of anti-obesity agents for hormonal, reproductive, metabolic, and psychological outcomes in polycystic ovary syndrome (PCOS) to inform the 2023 update of the International Evidence-based Guideline on PCOS. We searched Medline, EMBASE, PsycInfo, and CINAHL until July 2022 with a 10-year limit to focus on newer agents. Eleven trials (545 and 451 participants in intervention and control arms respectively, 12 comparisons) were included. On descriptive analyses, most agents improved anthropometric outcomes; liraglutide, semaglutide and orlistat appeared superior to placebo for anthropometric outcomes. Meta-analyses were possible for two comparisons (exenatide vs. metformin and orlistat + combined oral contraceptive pill [COCP] vs. COCP alone). On meta-analysis, no differences were identified between exenatide versus metformin for anthropometric, biochemical hyperandrogenism, and metabolic outcomes, other than lower fasting blood glucose more with metformin than exenatide (MD: 0.10 mmol/L, CI 0.02-0.17, I2 = 18%, 2 trials). Orlistat + COCP did not improve metabolic outcomes compared with COCP alone (fasting insulin MD: -8.65 pmol/L, -33.55 to 16.26, I2 = 67%, 2 trials). Published data examining the effects of anti-obesity agents in women with PCOS are very limited. The role of these agents in PCOS should be a high priority for future research.
CC BYText from Europe PMC. Highlighted sentences are the source of results.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanSystematic reviewEfficacy outcome

    In women with polycystic ovary syndrome, liraglutide appeared superior to placebo for anthropometric outcomes on descriptive analysis.

    In plain wordsIn women with polycystic ovary syndrome, liraglutide appeared to beat placebo for body measures such as weight, in a descriptive summary.

    Peptide
    Liraglutide
    Outcome
    Not applicableAnthropometric outcomes versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    liraglutide, semaglutide and orlistat appeared superior to placebo for anthropometric outcomes
    1 context sentence
    Summary · context
    Eleven trials (545 and 451 participants in intervention and control arms respectively, 12 comparisons) were included.
  2. 02HumanSystematic reviewEfficacy outcome

    In women with polycystic ovary syndrome, semaglutide appeared superior to placebo for anthropometric outcomes on descriptive analysis.

    In plain wordsIn women with polycystic ovary syndrome, semaglutide appeared to beat placebo for body measures such as weight, in a descriptive summary.

    Peptide
    Semaglutide
    Outcome
    Not applicableAnthropometric outcomes versus placebo
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated

    Source sentences

    Summary
    liraglutide, semaglutide and orlistat appeared superior to placebo for anthropometric outcomes
    1 context sentence
    Summary · context
    Eleven trials (545 and 451 participants in intervention and control arms respectively, 12 comparisons) were included.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 3Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 2

    9 Oct 2026, 03:06 UTC

    Study data updated · source update from Europe PMC

  3. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.